Cell therapy (Stem-cell derived) · developed by Mesoblast International Sàrl
Chondrogen is a cell therapy made of ex vivo cultured adult human mesenchymal stem cells, given by intra-articular injection. It is studied for recovery following partial medial meniscectomy, a knee surgery.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00702741 | Phase 1/2 | Recovery Following Partial Medial Meniscectomy | Completed | MESO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Recovery Following Partial Medial Meniscectomy
Updated Oct 18, 2026. Something wrong or missing? Report it on the MESO page.
See MESO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MESO catalysts and pipeline →